<DOC>
	<DOCNO>NCT01162876</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics pharmacodynamics saxagliptin administer breakfast 14 consecutive day patient type 2 diabetes mellitus .</brief_summary>
	<brief_title>A Clinical Pharmacology Study Saxagliptin Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<criteria>Patients meet follow criterion include : 1 . HbA1c level ≥7.0 % &lt; 9.0 % 2 . Fasting glucose level ≥130mg/dL &lt; 210mg/dL 3 . Patients capable give informed consent 4 . Patients able take contraceptive measure avoid pregnancy patient patient 's partner entire study period 4 week completion study Patients type 1 diabetes mellitus ; patient diabetes mellitus due specify drug , mechanism , disease ; patient gestational diabetes mellitus Patients medical history diabetic coma Patients heart failure Patients complication active chronic hepatitis hepatic cirrhosis Patients undergoing treatment glomerular disease diabetic nephropathy Patients history complication malignant tumor</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Diabetes , Type 2</keyword>
</DOC>